Project Grant R21NS140745
Award Date
5/9/25
Completion Date
4/30/27
Dollars Obligated
$603K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This $1,511,970 federal Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The research aims to identify CNS-penetrant GPR34 antagonists as potential non-opioid-based therapeutics for neuropathic pain, which affects 15-20 million people in the U.S. and has limited effective treatments. The project...
The Project Grant award R61NS133704, totaling $1,846,202.00, was provided by the National Institute of Neurological Disorders and Stroke under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Duke University. The primary objective is to develop potent, selective, and peripherally-restricted antagonists of the adrenergic receptor beta-3 (ADRB3) for the treatment of chronic primary pain conditions affecting over 100 million people. This will involve: 1) developing novel ADRB3...
This federal Project Grant award of $1,587,553.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development and characterization of novel central nervous system (CNS)-penetrant 5-HT3 receptor antagonists as potential treatments for neuropathic pain. The multi-institution research team, led by the Washington University, will use computational drug design approaches, such as structure-based...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $675,107 to Northeastern University to conduct research on the development of non-opioid, non-addictive analgesics for treating neuropathic pain. The project aims to design and synthesize novel "dualsteric modulators" that can act as both non-psychoactive...
This $1,563,778 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop new non-opioid pain treatments by exploring the role of the equilibrative nucleoside transporter 1 (ENT1) as a novel target for neuropathic pain. The funding will support three key activities: 1) in vivo validation of ENT1 as a neuropathic pain target, 2) in vitro and ex vivo characterization of ENT1...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $664,772 to support research on a novel, non-opioid analgesic mechanism for treating high-impact chronic pain. The primary awardee, The University of Texas Southwestern Medical Center, will investigate the signaling pathways involving the neurotensin receptor 2 (NTSR2)...
This $650,079 federal Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports the development and optimization of novel small-molecule probes targeting alpha9-containing nicotinic acetylcholine receptors (α9*-nAChRs) for the treatment of chronic inflammatory and neuropathic pain. The 5-year research project, awarded to Northeastern University,...
This $2,068,842 federal Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to dissect the role of prefrontal cortex dynorphin circuits in modulating different pain states. The research aims to identify pain-induced adaptations in the prefrontal cortical dynorphin/kappa-opioid receptor system and its influence on pain-induced maladaptive behavior and nociception. Through...
This Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program, provides $818,360.00 in funding to the University of Southern California to develop novel angiotensin AT2 receptor antagonists for the treatment of neuropathic pain. The project aims to optimize lead compounds identified through the university's structure-based drug...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,314,276.00 in funding to Emory University to develop novel methods for selectively stimulating nociceptors and measuring nociceptive-specific brain activations. The project aims to overcome limitations in current experimental pain testing by identifying skin regions devoid of innocuous warm fibers, allowing for unbiased...